Patents Represented by Attorney, Agent or Law Firm J. Michael Dixon
  • Patent number: 8304252
    Abstract: The present invention is directed to a regio-and stereoselective bioconversion of selected aliphatic dinitriles into corresponding cyanocarboxylic acids. More particularly, the present invention provides methods for the conversion of 2-isobutyl-succinonitrile into (S)-3 cyano-5-methylhexanoic acid, which is a useful intermediate in the synthesis of (S)-3(aminomethyl)-5-methylhexanoic acid (pregabalin). Pregabalin can be used for treating certain cerebral diseases, for example, in the treatment and prevention of seizure disorders, pain, and psychotic disorders.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: November 6, 2012
    Assignee: Pfizer Inc.
    Inventors: Michael P. Burns, Justin K. Weaver, John Wing Wong
  • Patent number: 8283471
    Abstract: The present invention relates to a succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: October 9, 2012
    Assignee: Pfizer, Inc.
    Inventors: Caroline Proulx-Lafrance, Patrick Robert Verhoest
  • Patent number: 8158156
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: April 17, 2012
    Assignee: Alpharma Pharmaceuticals, LLC
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • Patent number: 8153814
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 10, 2012
    Assignees: Pfizer Limited, Icagen, Inc.
    Inventors: Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David Simon Millan, David James Rawson, Steven Michael Reister, Kosuke Sasaki, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Christopher William West, Shulan Zhou
  • Patent number: 8134007
    Abstract: The present invention relates to compounds of the formula (I): and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: March 13, 2012
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Karl Richard Gibson, Mark Ian Kemp, Cedric Poinsard, Blanda Luzia Stammen, Stephen Martin Denton, Melanie Susanne Glossop
  • Patent number: 8134023
    Abstract: Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: March 13, 2012
    Assignee: Pfizer Inc
    Inventors: Shanghui Hu, Carlos Alberto Martinez, Junhua Tao, William Eugene Tully, Patrick Kelleher, Yves Dumond
  • Patent number: 8133883
    Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: March 13, 2012
    Assignee: Pfizer Inc.
    Inventors: Jonathan M. Cohen, Syed M Shah, Christian L. Ofslager, Mahdi B. Fawzi
  • Patent number: 8088804
    Abstract: Described herein are N-hydroxyamide antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) each indicates a point of attachment.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: January 3, 2012
    Assignee: Pfizer Inc.
    Inventors: Rakesh Kumar Jain, Mikhail Fedorovich Gordeev, Jason Gustaf Lewis, Charles Francavilla
  • Patent number: 7214694
    Abstract: Compounds of formula (I): wherein the substituents are as defined herein, and their salt, solvates, and prodrugs are procollagen C-proteinase (PCP) inhibitors useful in treating conditions mediated by PCP.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: May 8, 2007
    Assignee: Pfizer Inc
    Inventors: Usa Datta, Paul Vincent Fish, Kim James, Gavin Alistair Whitlock
  • Patent number: 7169890
    Abstract: The invention regards a process for the production of ramoplanin-like derivatives of formula (I): RAMO-NC—CO—R (I), wherein the radical R represents a hydrocarbon radical and the portion RAMO-NH— represents deacylated ramoplanin, any of its factors or ramoplanose. The compound of Formula (I) are obtained by reacting a carboxylic acid R—COOH with deacylated ramoplanin, any of its factors or ramoplanose protected on the ornitine amino groups. New compounds wherein the hydrocarbon radical R is different form those characaterizing the ramoplanin and ramoplanose natural products and their tetrahydro-derivatives are calimed. The new compounds have the same or better antinfective activity, lower haemolytic effect and better tolerability profile than ramoplanin.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: January 30, 2007
    Assignee: Vicuron Pharmaceuticals Inc.
    Inventors: Romeo Ciabatti, Sonia Maffioli, Anna Checchia, Gabriella Romano, Gianpaolo Candiani, Gianbattista Panzone
  • Patent number: 7115745
    Abstract: The present invention is directed to a new class of 6-benzyl urea/thiourea-quinolin-2-one derivatives and 2-oxo-6-benzylurea/thiourea-chromene derivatives. These compound are androgen antagonists and are useful in the treatment of alopecia, acne and other conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 3, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7098340
    Abstract: The present invention is directed to a new class of 6-benzylsulfonamido-quinoline/chromene derivatives, to their use as androgen antagonists, and to formulations containing these androgen antagonists.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 29, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7074933
    Abstract: The invention is directed to a new class of quinolin-zene and z-exc chromen compounds that have been derivatized at the 6-position with a urea or this urea moet, and to then use as androgen antagonists.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: July 11, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7064207
    Abstract: The present invention is directed to a new class of 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives to their use as androgen antagonists, and to relieve conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 20, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams
  • Patent number: 7057048
    Abstract: The present invention is directed to a new class of 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives to their use as androgen antagonists, and to relieve conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 6, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams
  • Patent number: 7009052
    Abstract: The present invention is directed to a new class of 6-sulfonamide quinoline and chromene derivative and to their use as androgen antagonists.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: March 7, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams
  • Patent number: 6984652
    Abstract: Compounds comprising an indazolyl group and a thiazolyl group, preferably 7-substituted 3-(thiazol-2-yl)-1H-indazole compounds in which the indazolyl group and a thiazolyl group are each independently optionally substituted, are useful for the treatment or prophylaxis of bacterial infections in mammals. The compounds are believed to function by inhibiting gyrase B.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: January 10, 2006
    Assignee: Warner-Lambert Company LLC
    Inventors: Kraig Yager, Shaosong Chu, Krzysztof Appelt, Xiaoming Li
  • Patent number: 6960604
    Abstract: The invention provides thiazolidinedione, oxadiazolidinedione, and triazolone compounds of Formula (I) which compounds are thyroid receptor ligands. The invention further provides pharmaceutical compositions and kits comprising such compounds and methods of treating obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer, diabetes, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesterolemia, depression, and osteoporosis using such compounds.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: November 1, 2005
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventor: Yuan-Ching P. Chiang
  • Patent number: 6930107
    Abstract: The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 to R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: August 16, 2005
    Assignee: Pfizer Inc.
    Inventors: Robert L. Dow, Yuan-Ching P. Chiang, Kimberly G. Estep
  • Patent number: 6924310
    Abstract: The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: August 2, 2005
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Yuan-Ching P. Chiang, Gary E. Aspnes, Kimberly G. Estep